Viatris (XSWX:VTRS) EPS without NRI: CHF1.96 (TTM As of Mar. 2026)


XSWX:VTRS Viatris Inc XSWX:VTRS
60 GF Score
Price CHF13.06
GF Value CHF8.89
! 8 Warning Signs
View Full Analysis

What is Viatris EPS without NRI?

Viatris XSWX:VTRS +0.62% 60 EPS without NRI is CHF1.96 as of Mar. 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review. Among 786 Drug Manufacturers companies, Viatris ranks worse than 76.34% on this metric.

Viatris's earnings per share without non-recurring items for the three months ended in Mar. 2026 was CHF0.47. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.96.

During the past 12 months, Viatris's average earnings per share (NRI) Growth Rate was -1.20% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -11.10% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Viatris's EPS without NRI or its related term are showing as below:

XSWX:VTRS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -15.2   Med: 8.6   Max: 65.6
Current: -11.1

During the past 13 years, Viatris's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 65.60% per year. The lowest was -15.20% per year. And the median was 8.60% per year.

XSWX:VTRS's 3-Year EPS without NRI Growth Rate is ranked worse than
76.34% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs XSWX:VTRS: -11.10

Viatris's EPS (Diluted) for the three months ended in Mar. 2026 was CHF0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-0.21.

Viatris's EPS (Basic) for the three months ended in Mar. 2026 was CHF0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-0.21.


Viatris  (XSWX:VTRS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Viatris EPS without NRI Related Terms


Viatris EPS without NRI Historical Data

* Premium members only.

The historical data trend for Viatris's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris EPS without NRI Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.75 3.12 2.53 2.36 1.87

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.50 0.53 0.45 0.47

XSWX:VTRS vs NBIX, UTHR, ELAN: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Viatris's PE Ratio without NRI falls into.


XSWX:VTRS
60GF Score
Viatris Inc XSWX:VTRS
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of CHF1.96 mean?
Viatris (XSWX:VTRS) has a EPS without NRI of CHF1.96 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Viatris and its competitors. According to the industry distribution chart, Viatris ranks #600 out of 786 companies in the Drug Manufacturers industry, placing it in the top 76.3%.
Is Viatris' EPS without NRI too high?
Viatris' current EPS without NRI is CHF1.96. Based on the distribution chart, Viatris ranks #600 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' EPS without NRI compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #600 out of 786 companies for EPS without NRI. This places Viatris in the lower half of its industry. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current EPS without NRI is CHF1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current EPS without NRI of CHF1.96. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current EPS without NRI is CHF1.96. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current EPS without NRI is CHF1.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.

Key valuation signals for XSWX:VTRS:

  • EPS without NRI: CHF1.96
  • GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for XSWX:VTRS

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.06
Price
CHF8.89
GF Value